Ocugen, Inc. (OCGN)
1.35
+0.03
(+2.27%)
USD |
NASDAQ |
Sep 03, 16:00
1.35
0.00 (0.00%)
After-Hours: 20:00
Ocugen Research and Development Expense (TTM) : 42.81M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 42.81M |
| March 31, 2026 | 39.60M |
| December 31, 2025 | 37.87M |
| September 30, 2025 | 35.49M |
| June 30, 2025 | 33.40M |
| March 31, 2025 | 34.25M |
| December 31, 2024 | 31.55M |
| September 30, 2024 | 30.86M |
| June 30, 2024 | 29.80M |
| March 31, 2024 | 36.05M |
| December 31, 2023 | 39.39M |
| September 30, 2023 | 48.85M |
| June 30, 2023 | 57.42M |
| March 31, 2023 | 51.86M |
| December 31, 2022 | 49.60M |
| September 30, 2022 | 39.65M |
| June 30, 2022 | 30.30M |
| March 31, 2022 | 40.15M |
| December 31, 2021 | 35.11M |
| September 30, 2021 | 29.58M |
| June 30, 2021 | 31.37M |
| March 31, 2021 | 13.66M |
| December 31, 2020 | 12.44M |
| September 30, 2020 | 12.61M |
| June 30, 2020 | 5.841M |
| Date | Value |
|---|---|
| March 31, 2020 | 5.945M |
| December 31, 2019 | 8.086M |
| September 30, 2019 | 9.254M |
| June 30, 2019 | 9.510M |
| March 31, 2019 | 12.73M |
| December 31, 2018 | 12.22M |
| September 30, 2018 | 12.67M |
| June 30, 2018 | 14.60M |
| March 31, 2018 | 14.35M |
| December 31, 2017 | 15.57M |
| September 30, 2017 | 17.52M |
| June 30, 2017 | 18.91M |
| March 31, 2017 | 20.50M |
| December 31, 2016 | 21.58M |
| September 30, 2016 | 22.03M |
| June 30, 2016 | 23.00M |
| March 31, 2016 | 23.06M |
| December 31, 2015 | 23.24M |
| September 30, 2015 | 22.05M |
| June 30, 2015 | 29.44M |
| March 31, 2015 | 28.27M |
| December 31, 2014 | 25.86M |
| September 30, 2014 | 24.82M |
| June 30, 2014 | 15.14M |
| March 31, 2014 | 13.38M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Biogen, Inc. | 1.736B |
| Gilead Sciences, Inc. | 5.943B |
| MannKind Corp. | 76.88M |
| Vertex Pharmaceuticals, Inc. | 3.907B |